Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.37 +0.27 (+1.49%)

Official Closing Price Updated: 7:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9 Next >

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

September 30, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

September 22, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

September 18, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

September 14, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

September 09, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 24, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

July 30, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

July 16, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

July 12, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

June 24, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

June 11, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

June 09, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

May 18, 2026

From Hagens Berman

Via Business Wire

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

May 13, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

May 04, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

March 28, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 02, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

February 19, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

February 10, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

January 29, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

January 22, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

December 18, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 06, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

November 07, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.